• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片类激动剂治疗中的持续时间困境。

The duration dilemma in opioid agonist therapy.

机构信息

Cornell Scott Hill Health Center, Ansonia, Connecticut.

Division of Chemical Dependency, Mount Sinai Beth Israel, New York City, New York.

出版信息

J Opioid Manag. 2021 Jul-Aug;17(4):353-358. doi: 10.5055/jom.2021.0668.

DOI:10.5055/jom.2021.0668
PMID:34533830
Abstract

OBJECTIVE

Studies dating back to 1964 consistently support the effectiveness of methadone as a maintenance treatment for opioid use disorder (OUD), and since 2003, the effectiveness of buprenorphine. Short-term detoxification has not proven to be an effective treatment, as it results in high relapse rates when compared with maintenance treatment with an opioid agonist therapy (OAT). The question about the duration of maintenance treatment for OUD has been debated with recommendations ranging from a minimum of 1 year, 2 years, to indefinitely. Other factors such as misconceptions, regulations, and insurance barriers also have an impact on the duration dilemma of OAT.

DESIGN

There were no a priori criteria for article inclusion and this is not a structured literature review. It is a review of articles of convenience from 1964 to 2018.

MAIN OUTCOME MEASURE

This paper aims to address the dilemma of the ideal duration of OAT and to discuss the factors that could affect this decision.

RESULTS

Sustained OAT has had significantly better long-term outcomes than short-term detoxification or time limited maintenance. Optimal outcomes are dependent on adequate treatment duration.

CONCLUSIONS

Addiction is a chronic brain disease and its treatment should be similar to the treatment of other chronic medical and psychiatric diseases. Long-term, sometimes lifetime, continuation of OAT for the treatment of OUD results in optimal outcomes when measuring morbidity and mortality. The accumulated evidence does not support any arbitrary limitation to the duration of OAT.

摘要

目的

早在 1964 年,就有研究一致支持美沙酮作为治疗阿片类药物使用障碍(OUD)的维持治疗的有效性,自 2003 年以来,丁丙诺啡的有效性也得到了证实。与阿片类激动剂治疗(OAT)的维持治疗相比,短期戒毒治疗并未被证明是一种有效的治疗方法,因为它会导致较高的复发率。OUD 的维持治疗时间长短问题一直存在争议,建议的维持治疗时间从至少 1 年、2 年到无限期不等。其他因素,如误解、法规和保险障碍,也会对 OAT 的持续时间产生影响。

设计

本文没有事先规定的纳入标准,也不是一篇结构化的文献综述。这是对 1964 年至 2018 年期间方便收集的文章的回顾。

主要观察指标

本文旨在解决 OAT 理想持续时间的困境,并讨论可能影响这一决策的因素。

结果

与短期戒毒或限时维持治疗相比,持续的 OAT 具有显著更好的长期效果。最佳效果取决于足够的治疗持续时间。

结论

成瘾是一种慢性脑部疾病,其治疗方法应与其他慢性医学和精神疾病的治疗方法相似。长期、有时是终身的 OAT 持续治疗 OUD,在衡量发病率和死亡率时可带来最佳效果。现有证据并不支持对 OAT 的持续时间进行任何任意限制。

相似文献

1
The duration dilemma in opioid agonist therapy.阿片类激动剂治疗中的持续时间困境。
J Opioid Manag. 2021 Jul-Aug;17(4):353-358. doi: 10.5055/jom.2021.0668.
2
Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.阿片类药物使用障碍治疗的启动和持续:接受成瘾咨询和医院提供者的患者的定性研究。
J Gen Intern Med. 2022 Aug;37(11):2786-2794. doi: 10.1007/s11606-021-07305-3. Epub 2022 Jan 3.
3
Underrepresentation of diverse populations and clinical characterization in opioid agonist treatment research: A systematic review of the neurocognitive effects of buprenorphine and methadone treatment.阿片类激动剂治疗研究中不同人群的代表性不足及临床特征:丁丙诺啡和美沙酮治疗神经认知效应的系统评价
J Subst Abuse Treat. 2022 Apr;135:108644. doi: 10.1016/j.jsat.2021.108644. Epub 2021 Oct 23.
4
Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?新冠疫情期间德国阿片类激动剂治疗实践的变化:医生们做了什么,他们希望继续做什么?
Eur Addict Res. 2023;29(5):323-332. doi: 10.1159/000531593. Epub 2023 Aug 9.
5
Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.监禁人员中与阿片类药物相关的治疗、干预措施和结果:系统评价。
PLoS Med. 2019 Dec 31;16(12):e1003002. doi: 10.1371/journal.pmed.1003002. eCollection 2019 Dec.
6
Utilization of buprenorphine and methadone among opioid users who inject drugs.阿片类药物使用者中使用丁丙诺啡和美沙酮的情况。
Subst Abus. 2018 Jan 2;39(1):83-88. doi: 10.1080/08897077.2017.1363844. Epub 2017 Sep 18.
7
Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.阿片类物质使用障碍中丁丙诺啡和美沙酮治疗的建议:一项欧洲共识
Expert Opin Pharmacother. 2017 Dec;18(18):1987-1999. doi: 10.1080/14656566.2017.1409722. Epub 2017 Dec 3.
8
Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.描述 2012-2018 年加拿大不列颠哥伦比亚省阿片类激动剂治疗中断趋势。
Drug Alcohol Depend. 2021 Aug 1;225:108799. doi: 10.1016/j.drugalcdep.2021.108799. Epub 2021 May 29.
9
Pharmacological treatment of opioid use disorder in pregnancy.妊娠期阿片类药物使用障碍的药物治疗。
Semin Perinatol. 2019 Apr;43(3):141-148. doi: 10.1053/j.semperi.2019.01.003. Epub 2019 Jan 21.
10
Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.2006-2016 年加拿大温哥华阿片类药物使用障碍级联护理参与趋势。
Drug Alcohol Depend. 2018 Aug 1;189:90-95. doi: 10.1016/j.drugalcdep.2018.04.026. Epub 2018 May 29.

引用本文的文献

1
Drug Overdose Death Following Substance Use Disorder Treatment Termination in New York City: A Retrospective Longitudinal Cohort Study.纽约市物质使用障碍治疗终止后药物过量死亡:一项回顾性纵向队列研究。
J Urban Health. 2024 Oct;101(5):1045-1057. doi: 10.1007/s11524-024-00893-5. Epub 2024 Aug 2.
2
Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature.静脉注射美沙酮治疗围手术期和慢性癌痛:文献综述。
Drugs. 2023 Jul;83(10):865-871. doi: 10.1007/s40265-023-01876-7. Epub 2023 Jun 13.